Having worked in pharmaceutical development for more than 15 years, Adam has held positions in drug manufacturing, quality assurance, and regulatory affairs, and he is currently the Director of Regulatory Intelligence and Policy at Daiichi Sankyo, Inc.. He has direct experience in a variety of drug classes including radiopharmaceuticals, cell and gene therapies, and antibody drug conjugates as well as medical devices. Currently, his interests revolve around the intersection of innovation, patient safety, and the current deregulatory nature of the US FDA.